About Edwards Lifesciences
Edwards Lifesciences, headquartered in Irvine, California, is the global leader in structural heart disease and critical care monitoring, best known for transcatheter heart valves.
Milestones
Milestones as listed on edwards.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on edwards.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Todd J. Brinton, M.D.
Products & Services
Products and services as listed on edwards.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Transcatheter Heart
Transcatheter heart valve technologies delivered without open-heart surgery.
Source: edwards.comTranscatheter Mitral and Tricuspid Technologies
Catheter-based therapies for mitral and tricuspid valve disease.
Source: edwards.comSurgical Heart
Surgical heart valve products and related solutions.
Source: edwards.comAdvanced Tissue
Advanced tissue technology used in heart valve products.
Source: edwards.comSites in Ireland
Limerick (National Technology Park, Plassey)
Recently opened manufacturing plant in the National Technology Park, Plassey.
Source: edwards.comSites as listed on edwards.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Pipeline & Regulatory Record
What public registers list for Edwards Lifesciences: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 6 Oct 2026.
Clinical trials 41 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|---|---|
| Autus Valve Pivotal Study NCT05006404 · Congenital Heart Disease |
Not applicable | Active, closed |
| ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System NCT05686317 · Heart Failure |
Not applicable | Active, closed |
| TRISCEND JAPAN Study NCT05760989 · Tricuspid Valve Regurgitation, Heart Valve Diseases |
Not applicable | Active, closed |
| TVMR With the Innovalve System Trial - Pilot Study in Italy NCT05010746 · Mitral Valve Regurgitation (Degenerative or Functional) |
Not applicable | Active, closed |
| Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve NCT05526560 · Mitral Stenosis, Mitral Valve Insufficiency |
Observational | Active, closed |
| INSPIRIS China PMCF Study NCT05404880 · Aortic Valve Replacement |
Observational | Active, closed |
| ALTERRA Post-Approval Study NCT05378386 · Pulmonary Valve Insufficiency, Complex Congenital Heart Defect |
Observational | Active, closed |
| China S3 PMS: SAPIEN 3 China Post Market Registry Study NCT05168826 · Aortic Stenosis, Severe |
Observational | Active, closed |
| COMPASSION S3 Post-Approval Study NCT04860765 · Complex Congenital Heart Defect, Dysfunctional RVOT Conduit |
Observational | Active, closed |
| TRISCEND II Pivotal Trial NCT04482062 · Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency |
Not applicable | Active, closed |
Showing 10 of 41, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Group (Edwards Lifesciences): founded 1958, headquarters Irvine, website EdwardsLifesciences.com. Wikidata Q16966841 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Edwards Lifesciences. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Edwards Lifesciences Corporation files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $6.07bn | $1.08bn | 17.8% | $1.07bn | 10-K 2026 |
| Dec 2024 | $5.44bn | $1.05bn | 19.4% | $4.17bn | 10-K 2026 |
| Dec 2023 | $5.01bn | $963m | 19.2% | $1.40bn | 10-K 2026 |
| Dec 2022 | $4.46bn | $844m | 18.9% | $1.52bn | 10-K 2025 |
| Dec 2021 | $5.23bn | $903m | 17.3% | $1.50bn | 10-K 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 2 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Edwards Lifesciences Limited External company | 905819 | 1999 | — |
| Edwards Lifesciences Ireland, Limited LTD - Private Company Limited by Shares | 616926 | 2017 | Dec 2024 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Edwards Lifesciences Corporation as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.